Clinical Trial Update: Effects of Long-Acting GLP-1 (Glucagon-like Peptide-1) or Dual Incretin (GLP-1 and GIP [Glucose-dependent Insulinotropic Peptide]) Modulation on Gastric Motor Functions [Phase 4]

View source ↗

Summary

A Phase 4 Mayo Clinic trial is evaluating how long-acting GLP-1 or dual incretin modulation affects gastric motor functions in obesity; the study status is ACTI…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity

Drugs mentioned

• Dual incretin (GLP-1 and GIP) modulator (GLP-1 and GIP receptor modulator)
• GLP-1 receptor agonist (long-acting) (glucagon-like peptide-1 receptor agonist)

Snippet

Sponsor: Mayo Clinic | Conditions: Obesity | Phase 4 | Status: ACTIVE_NOT_RECRUITING